Nexentis Technologies (NASDAQ:NXTS – Get Free Report) and Theravance Biopharma (NASDAQ:TBPH – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability.
Valuation and Earnings
This table compares Nexentis Technologies and Theravance Biopharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nexentis Technologies | $210,000.00 | 3.55 | -$4.00 million | ($96.07) | -0.01 |
| Theravance Biopharma | $104.31 million | 8.48 | $105.89 million | $1.01 | 16.86 |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Nexentis Technologies and Theravance Biopharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nexentis Technologies | 1 | 0 | 0 | 0 | 1.00 |
| Theravance Biopharma | 0 | 7 | 0 | 0 | 2.00 |
Theravance Biopharma has a consensus price target of $19.00, suggesting a potential upside of 11.57%. Given Theravance Biopharma’s stronger consensus rating and higher probable upside, analysts plainly believe Theravance Biopharma is more favorable than Nexentis Technologies.
Insider and Institutional Ownership
61.2% of Nexentis Technologies shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 6.5% of Nexentis Technologies shares are held by company insiders. Comparatively, 7.6% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Nexentis Technologies and Theravance Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nexentis Technologies | N/A | -304.79% | -178.91% |
| Theravance Biopharma | 51.58% | -0.77% | -0.46% |
Volatility & Risk
Nexentis Technologies has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500.
Summary
Theravance Biopharma beats Nexentis Technologies on 12 of the 13 factors compared between the two stocks.
About Nexentis Technologies
N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company’s products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.
About Theravance Biopharma
Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.
Receive News & Ratings for Nexentis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexentis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
